Multifocal Demyelinative Leukoencephalopathy Associated with 5-Fluorouracil and Levamisole

REFERENCES

• Moertel CG, Fleming TR, MacDonald JS, et al. Levamisole and fluorouracil for adjunct therapy of resected colon car-cinoma. N Engl J Med 1990; 322: 352–8.
   PubMed Web of Science ®Google Scholar
• Chen RC, Hinton DR, Leichman L, et al. Multifocal leukoencephalopathy associated with levamisole and 5-fluorouracil: case report. Neurosurgery 1994; 35: 1138–43.
   PubMedGoogle Scholar
• Fassas A, Gattani A, Morgello S. Cerebral demyelination with 5-fluorouracil and levamisole. Cancer Invest 1994; 12: 379–83.
   Web of Science ®Google Scholar
• Hook CC, Kimmel DW, Kvols LK, et al. Multifocal infl-ammatory leukoencephalopathy with 5-fluorouracil and levamisole. Ann Neurol 1992; 31: 262–7.
   PubMed Web of Science ®Google Scholar
• Kimmel DW, Schutt AJ. Multifocal leukoencephalopathy: occurrence during 5-fluorouracil and levamisole therapy and resolution after discontinuation of chemotherapy. Mayo Clin Proc 1993; 68: 363–5.
   PubMed Web of Science ®Google Scholar
• Neu IS. Multifocal inflammatory leukoencephalopathy caused by adjuvant therapy with 5-fluorouracil and levamisole after resection for an adenocarcinoma of the colon. Acta Neurol Scand 1993; 87: 1, 70.
   PubMedGoogle Scholar
• Boileau G, Piro AJ, Lahiri SR, Hall TC. Cerebellar ataxia during 5-fluorouracil (NSC-19893) therapy. Cancer Chemother Rep 1971; 55: 595–8.
   PubMedGoogle Scholar
• Moertel CG, Reitemeier RJ, Bolton CF, Shorter RG. Cere-bellar ataxia associated with fluorinated pyrimidine therapy. Cancer Chemother Rep 1964; 41: 15–8.
   PubMedGoogle Scholar
• Riehl JL, Brown WJ. Acute cerebellar syndrome secondary to 5-fluorouracil therapy. Neurology 1964; 14: 961–7.
   PubMed Web of Science ®Google Scholar
• Lynch HT, Proszcz CP, Albano WA, Lynch JF. Organic brain syndrome secondary to 5-fluorouracil toxicity. Dis Colon Rectum 1981; 24: 130–1.
   PubMed Web of Science ®Google Scholar
• Okeda R, Karakama T, Kimura S, Toizumi S, Mithushima T, Yokoyama Y. Neuropathologic study on chronic neuro-toxicity of 5-fluorouracil and its masked compounds in dogs. Acta Neuropathol (Berl) 1984; 63: 333–4.
   Google Scholar
• Koenig HK, Patel A. Biochemical basis for fluorouracil tox- icity: the role of Kreb's cycle inhibition by fluoroacetate. Arch Neurol 1970; 23: 155–60.
   PubMed Web of Science ®Google Scholar
• Parkinson DR, Jerry LM, Shibata HR, et al. Complications of cancer immunotherapy with levamisole. Lancet 1977; 1: 1129–32.
   PubMed Web of Science ®Google Scholar
• Symoens J, Veys E, Mielants M, Pinals R. Adverse reac-tions to levamisole. Cancer Treat Rep 1978; 62: 1721–30.
   PubMedGoogle Scholar
• Prieur AM, Buriot D, Lefur JM, Griscelli C. Possible toxic-ity of levamisole in children with rheumatoid arthritis. J Pediatr 1978; 93: 304–5.
   PubMedGoogle Scholar
• Hunan Medical University. Analysis of 10 subjects with en-cephalopathy due to levamisole. Bull Hunan Med Univ 1989; 14: 1–6.
   Google Scholar
• Kimmel DW, Widjicks EF, Rodriguez M. Multifocal infl-ammatory leukoencephalopathy associated with levamisole therapy. Neurology 1995; 45: 374–6.
   Google Scholar
• Stevenson HC, Green I, Hamilton JM, Calabro BA, Parkinson DR. Levamisole: known effects on the immune system, clinical results, and further applications to the treat-ment of cancer. J Clin Oncol 1991; 9: 2052–66.
   Google Scholar
• Dau PC, Johnson KP, Spitler LE. The effect of levamisole on cellular immunity in multiple sclerosis. Clin Exp Im-munol 1976; 26: 302–9.
   PubMedGoogle Scholar
• Hartung HP. Immune-mediated demyelination. Ann Neurol 1993; 33: 563–7.
   PubMedGoogle Scholar
• Noseworthy JH, Rodriguez M, Jiang NS, et al. TNF-alpha in multiple sclerosis. Neurology 1993; 43: Abstr 765S.
   Google Scholar
• Sharief MK, Hentges R. Association between tumor necro-sis factor-a and disease progression in patients with multiple sclerosis. N Engl J Med 1991; 325: 467–72.
   PubMed Web of Science ®Google Scholar
• Tsukada N, Miyagi K, Matsuda M, et al. Tumor necrosis factor and interleukin-1 in the CSF and sera of patients with multiple sclerosis. J Neurol Sci 1991; 102: 230–4.
   Google Scholar
• Benvenuto R, Paroli M, Buttinelli C, et al. Tumor necrosis factor-a synthesis by cerebrospinal fluid derived T-cell clones from patients with multiple sclerosis. Clin Exp Im-munol 1991; 84: 97–102.
   PubMed Web of Science ®Google Scholar
• Merril JE, Strom SR, Ellison GW, Myers LW. In vitro study of mediators of inflammation in multiple sclerosis. J Clin Immunol 1989; 9: 84–96.
   PubMedGoogle Scholar
• Hofman FM, von Hanwehr RI, Dinarello CA, Mizel SB, Hinton D, Merril JE. Immunoregulatory molecules and IL-2 receptors identified in multiple sclerosis brain. J Immunol 1986; 136: 3239–45.
   PubMed Web of Science ®Google Scholar
• Hofman FM, Hinton DR, Johnson K, Merril JE. Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med 1989; 170: 607–12.
   PubMed Web of Science ®Google Scholar
• Imamura K, Suzumura A, Hayashi F, Marunouchi T. Cy-tokine production by peripheral blood monocytes/ macrophages in multiple sclerosis patients. Acta Neurol Scand 1993; 87: 281–5.
   PubMed Web of Science ®Google Scholar